In-vitro antimicrobial activity of HSR-903, a new fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae with quinolone resistance-associated alterations in GyrA and ParC

Journal of Antimicrobial Chemotherapy

Volumn 40, Issue 3, 1997, Pages 437-439

  Deguchi, Takashi ^a   Yasuda, Mitsuru ^a   Ishihara, Satoshi ^a   Takahashi, Yoshie ^b   Okezaki, Eiichi ^b   Nagata, Osamu ^b   Saito, Isao ^c   Kawada, Yukimichi ^a  

^a GIFU UNIVERSITY   (Japan)

^b Abbott Japan Co Ltd   (Japan)

^c TOKYO KYOSAI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 7 (7 AMINO 5 AZASPIRO[2.4]HEPT 5 YL) 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 8 METHYL 4 OXO 3 QUINOLINECARBOXYLIC ACID; CIPROFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; NEISSERIA GONORRHOEAE; NONHUMAN;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; GENES, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE; QUINOLONES; URETHRITIS;

EID: 0030763265     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/40.3.437     Document Type: Article

References (10)

1. Belland, R. J., Morrison, S. G., Ison, C. & Huang, W. M. (1994). Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Molecular Microbiology 14, 371-80.
2. Deguchi, T., Yasuda, M., Nakano, M., Oseki, S., Ezaki, T., Saito, I. et al. (1996). Quinolone-resistant Neisseria gonorrhoeae. Correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles. Antimicrobial Agents and Chemotherapy 40, 1020-3.
3. Okezaki, E., Watanabe, Y., Hirose, T., Yoshida, T., Aoki, Y. & Kato, H. (1995). Antibacterial activity of HSR-903, a new novel quinolone. In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995, Abstract F202, p. 148. American Society for Microbiology, Washington, DC.
4. Nishino, T., Takahashi, Y. & Otsuki, M. (1996). In vitro and in vivo antibacterial activity of HSR-903, a new quinolone. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996, Abstract F59, p. 110. American Society for Microbiology, Washington, DC.
5. National Committee for Clinical Laboratory Standards. (1993). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Third Edition. Approved Standard M7-A3. NCCLS, Villanova, PA.
6. Centers for Disease Control. (1993). 1993 sexually transmitted diseases treatment guidelines. Morbidity and Mortality Weekly Report 42, 57-9.
7. Tapsall, J. W., Shultz, T. R., Lovett, R. & Munro, R. (1992). Failure of 500 mg ciprofloxacin therapy in male urethral gonorrhoea. Medical Journal of Australia 156, 143.
8. Tapsall, J. W., Limnios, E. A., Thacker, C., Donovan, B., Lynch, S. D., Kirby, L. J. et al. (1995). High-level quinolone resistance in Neisseria gonorrhoeae: a report of two cases. Sexually Transmitted Diseases 22, 310-1.
9. Umemura, K., Mizuno, K. & Nakashima, M. (1996). Pharmacokinetics and safety of HSR-903 in healthy volunteers. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996, Abstract F60, p. 100. American Society for Microbiology, Washington, DC.
10. Kobayashi, H. & Shimura, M. (1985). Phase I study with Bay 09867 (ciprofloxacin). Chemotherapy (Tokyo) 33, Suppl. 7, 140-70.